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ABSTRACT 
 
COMPARISON OF ANTHROPOMETRIC MEASUREMENTS OF ABDOMINAL 
OBESITY AS PREDICTORS OF CARDIOMETABOLIC RISK FACTORS: 
NHANES 2011-2014  
by 
 
Carli Kettel 
 
June 2017 
 
Background It has been well established that screening tools for cardiometabolic diseases 
are less useful among obese populations as risk of these diseases is already high. 
However, research is lacking in regard to efficient screening tools for cardiometabolic 
diseases among normal weight and overweight populations.  
Objective This study compared the predictive strengths of body mass index (BMI), waist 
circumference (WC), waist-to-height ratio (WHtR), sagittal abdominal diameter (SAD), 
and SAD-to-height ratio (SADHtR) with respect to risk of cardiometabolic disorders in 
normal and overweight U.S. populations.  
Design This cross-sectional study utilized data from the 2011-2014 National Health and 
Nutrition Examination Survey.  
Participants/setting The sample included non-pregnant adults with a normal weight or 
overweight BMI status (≥ 20 years; n = 6482).  
Main outcome measures Each anthropometric measure was assessed for predicting risk 
of the following cardiometabolic disorders: hypertension (HTN), pre-diabetes, diabetes, 
 iv 
high total cholesterol, low high-density lipoprotein cholesterol (HDL-C), high non-HDL-
C, and high apolipoprotein B.  
Statistical analyses performed Simple and multiple logistic regression analyses 
compared the odds ratio of each anthropometric measure for each cardiometabolic 
disorder.  
Results When analyzed in separate models, BMI, WC, WHtR, SAD, and SADHtR 
identified all cardiometabolic risks. In simultaneous models with abdominal obesity 
measures, BMI no longer identified cardiometabolic risks (ORs <1.0), except low HDL-C. 
Among normal weight and overweight men, WHtR and SADHtR were stronger measures 
of cardiometabolic risk except low HDL-C. With normal weight and overweight women, 
WHtR and SADHtR were stronger measures of risk for hypertension and diabetes, while 
all of the abdominal obesity measures were similar in assessment of the remaining 
cardiometabolic risks. 
Conclusion In normal weight and overweight adults, anthropometric measures of 
abdominal obesity, especially those including a factor of height, are better predictors of 
cardiometabolic risk than BMI and should be a primary screening tool in this population.  
 v 
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CHAPTER I 
 
INTRODUCTION 
While obesity rates in the United States (U.S.) have started to plateau based on 
body mass index (BMI) measurements, abdominal obesity rates are on the rise according 
to measures of waist circumference.1,2 Abdominal obesity, as compared with other 
distributions of adipose tissue, has specifically been shown to be highly associated with 
chronic diseases such as diabetes, cardiovascular diseases, and other cardiometabolic 
diseases.3–5  
BMI has traditionally been used for the assessment of body weight but has been 
shown to lack accuracy in terms of body composition. Waist circumference (WC), waist-
to-height ratio (WHtR), and sagittal abdominal diameter (SAD) are several measures that 
are used in assessing abdominal obesity, with SAD being a relatively newer measure. 
SAD is measured in the supine position using a caliper positioned in the center of the 
abdomen, midway between the left and right iliac crests, measuring the height of the 
abdomen, which has been shown to be associated with the amount of visceral fat in the 
abdomen. Since SAD measurements only require the use of a specialized caliper, this 
allows for the measurement to be easy, fast, and inexpensive compared to the more 
precise yet radiation-emitting magnetic resonance imaging and dual-energy x-ray 
absorptiometry.  
To date, a limited number of large-scale studies have been conducted evaluating 
SAD with various cardiometabolic risks in the U.S. adult population. A study in 2005 by 
Smith et al. found among men that SAD was a stronger predictor of coronary heart 
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disease risk when divided by thigh circumference, known as the abdominal diameter 
index.6 In 2013, Gletsu-Miller et al. found that SAD was stronger at predicting levels of 
visceral adipose tissue, and thus the ability to predict risk of dysglycemia, than WC after 
controlling for confounding variables among a small sample of severely obese women.7 
Similarly, in 2014, Kahn et al. found that SAD was associated with dysglycemia among 
men and women independently from WC and BMI in a nationally representative sample 
of the U.S. population.8 These findings suggest that SAD may be a useful screening tool 
in the U.S. population among men and women. 
Since WHtR has often been shown to be a better measure of abdominal obesity 
than WC alone, it is logical to expect that SAD may be more effectively used as the 
SAD-to-height ratio (SADHtR).9,10 Few studies have investigated the relationship 
between metabolic risks and SADHtR, with only two studies having been conducted in 
the U.S. population. One of the studies focused on various abdominal measures and their 
associations with sex, age, socioeconomic status, and ethnicity, rather than comparing 
efficacy of abdominal obesity measures.11 The second study compared several 
anthropometric measures, including SAD and SADHtR, against cardiometabolic risks in 
a nationally representative sample of the U.S. population using National Health and 
Nutrition Examination Survey (NHANES) 2011-2012 data. In that study, Kahn et al. 
found that SADHtR and WHtR were better at predicting risk of cardiometabolic disorders 
than BMI12; suggesting that SADHtR may be a better screening tool, especially compared 
to BMI. 
Current disease-related research focuses primarily on the whole population, 
including obese individuals. However, obese populations are already at a high risk of 
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developing obesity-related diseases making abdominal obesity measures relatively 
unimportant. When determining a useful screening tool for obesity-related diseases, it is 
important to find a tool that also works well in normal weight and overweight 
populations. In some studies, an overweight status has been suggested to be protective, 
especially among older adults.13,14 However, recent research suggests that an overweight 
BMI status based on highest lifetime BMI is associated with increased risk of 
cardiovascular and all-cause mortality.15 This implies the need for an abdominal obesity 
measure among normal weight and overweight populations that may predict disease risk 
before the development of the disease occurs. Therefore, the objectives of this study 
include: 1) to compare the predictive strengths of BMI, WC, WHtR, SAD, and SADHtR 
with respect to risk of cardiometabolic disorders in the normal and overweight U.S. adult 
population; 2) to compare WC against WHtR, and SAD against SADHtR ratio to 
determine whether height improves the predictive strengths; and 3) to compare WC 
against SAD and WHtR and SADHtR to determine which provides the strongest 
predictive strength of cardiometabolic disorders. It is hypothesized that abdominal 
obesity measures will be stronger than BMI in cardiometabolic risk prediction and that 
the inclusion of height with these measures will only strengthen their ability to assess 
risk. 
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CHAPTER II 
 
LITERATURE REVIEW 
 
Abdominal Obesity 
Abdominal obesity is defined as excess fat in the stomach area and is recognized for 
its associated risks with cardiovascular disease and insulin resistance, compared to other 
areas of adiposity in the body.10,16,17 Abdominal adiposity includes subcutaneous and 
visceral fat, yet visceral fat has been shown to be more associated with chronic disease 
than subcutaneous fat.3–5 Subcutaneous fat may also play a role in abdominal obesity as it 
consists of two layers of fat, superficial and deep subcutaneous fat. Deep subcutaneous 
fat is suspected to play a bigger role in the development of chronic disease than 
superficial subcutaneous fat, specifically with insulin resistance.18  
 
Anthropometric Measurements 
Body Mass Index 
Body mass index (BMI) is the most commonly used screening tool in predicting 
high body fatness by clinicians. This likely is due to it being an easy and inexpensive 
measurement requiring only a scale and a stadiometer, both of which are available in all 
hospitals and clinics. While BMI is used to predict body fatness, it does not measure the 
body’s adiposity, possibly missing individuals at a higher disease risk that have a large 
waist or high visceral adiposity yet normal BMI. BMI is measured by dividing an 
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individual’s body weight in kilograms by their height in meters squared. The reference 
ranges for BMI include:  
• Underweight: < 18.5 kg/m2  
• Normal weight: 18.5-24.9 kg/m2 
• Overweight:  35-29.9 kg/m2 
• Obese: ≥ 30 kg/m2  
A recent study by Padwal et al. consisting of a cohort of over 49,000 individuals over the 
age of 40 investigated associations between BMI and body fat percentage with mortality. 
Adjusted Cox proportional hazards regression models revealed that a low BMI and high 
body fat percentage are independently associated with increased risk of mortality.19 
However, a low BMI in this case may suggest weight loss related to illness which 
generally also included a loss of lean body mass. Yu et al. also observed all-cause and 
cause-specific mortality related to BMI among several cohort studies, but were able to 
look at a weight history for each participant rather than a single BMI measurement.15 By 
using a weight history, Yu et al. were able to distinguish weight loss related to illness 
versus intentional weight loss. This revealed that individuals with unintentional weight 
loss were associated with an increased risk of mortality while those with intentional 
weight loss had a lower risk of mortality. Within their weight history, individuals with a 
maximum BMI of overweight or higher were associated with increased risk of all-cause 
mortality and cause-specific mortality, especially cardiovascular disease and coronary 
heart disease related deaths. Another recent cohort study by Tanamas et al. found that 
individuals with a normal BMI and an obese waist circumference (≥102 cm in men, ≥88 
cm in women), or an obese BMI and obese waist circumference were at increased risk of 
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all-cause and cardiovascular disease mortality compared to individuals with a normal 
BMI and waist circumference.20 With an inability to measure body composition, BMI 
should be used in combination with other assessments of adiposity to estimate disease 
risk. 
 
Waist Circumference 
Waist circumference (WC), another commonly used anthropometric measure, 
predicts disease risk by measuring central adiposity. This has been shown to be more 
beneficial for individuals in the normal or overweight BMI reference range, as the 
predictive power of WC is less effective beyond a BMI of 35 kg/m2.21 Central adiposity 
is more associated with cardiometabolic disease risk related to increased levels of visceral 
fat,22 perhaps making it a more ideal screening tool compared to BMI. The reference 
ranges for a high WC include: 
• Males: > 40” (101 cm)  
• Females: > 35” (88 cm)  
With gender-specific reference ranges, WC can be even more specific in predicting 
disease risk. In a large prospective study by Schulze et al., WC appeared to be the 
strongest measure among men and women in predicting risk of diabetes compared to 
BMI, waist-to-hip ratio (WHR), and waist-to-height ratio. However, once stratified by 
gender, waist-to-height ratio was a stronger predictor of diabetes risk among men and 
waist-to-height ratio and WC were deemed equal predictors of diabetes risk among 
women.23 A large cross-sectional study including only women residing in Australia, WC 
along with WHR and waist-to-height ratio were stronger predictors of CVD risk than 
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BMI. WC and WHR were specifically found to be independent predictors of CVD risk 
after controlling for BMI.24 Flegal et al. performed a study using data from NHANES 
1999-2004 comparing BMI, WC and waist-to-height ratio compared to body fat 
percentage. Overall, BMI, WC, and waist-to-height ratio were found to be similar 
indicators of body fatness, but are more closely associated with each other than with body 
fat percentage.13 With many abdominal obesity measures competing similarly or better 
than WC, a combination of obesity measures may be more beneficial in disease risk 
assessment. 
 
Waist-to-height Ratio 
Many studies support the use of waist-to-height ratio (WHtR) as the ideal 
screening tool for cardiometabolic disease and mortality.9,25–28 Unlike other 
anthropometric measurements, WHtR factors in height to account for larger/smaller 
statures and their associated waist sizes. An ideal WHtR has been suggested to be less 
than or equal to 0.5, while a high WHtR would be greater than 0.5. While this is a 
common used reference value in research, there is technically no standard reference value 
for WHtR. This has led to discussion of whether 0.5 is an acceptable reference value for 
whole population, or whether there should be different reference values between gender, 
age groups, and ethnicities. Bohr et al. found that 0.58 may be a better reference value in 
younger adults in the prediction of risk of metabolic syndrome.29 However, with study 
populations that include a wide range of ages, a WHtR reference value of 0.5 is often 
used as it appears to be generally accepted in current research.9  
 
 8 
Sagittal Abdominal Diameter 
Sagittal abdominal diameter (SAD) has become an increasingly more common 
anthropometric measure, as it has been included in the NHANES physiological 
measurements since 2011. SAD is measured in the supine position using a caliper 
positioned in the center of the abdomen, midway between the left and right iliac crests. 
This measures the height of the abdomen, which has been shown to be associated with 
the amount of visceral fat in the abdomen. While in the supine position, subcutaneous fat 
is believed to fall to the sides of the body leaving mostly visceral fat exposed, possibly 
identifying those with higher disease risk. With visceral fat being more correlated with 
cardiometabolic disease risk, SAD has become a more attractive screening tool. SAD 
does not currently have cut points to establish risk. Several studies have established their 
own versions of cut points but no standard has been established. Many studies have 
examined SAD and its ability to predict visceral adiposity compared to magnetic 
resonance imaging. While several dated studies found SAD unable to predict visceral 
adiposity,30,31 most studies have found an advantage to using SAD over the expensive and 
radiation-emitting MRI and CT scans.7,32–36 
 
Sagittal Abdominal Diameter-to-Height ratio 
While SAD has advantages over WC in measuring visceral fat, it still does not 
account for stature. With improvements in assessing risk by factoring height into WC, it 
could be assumed that height would improve disease risk assessment with SAD. Only one 
study has measured SAD-to-height ratio (SADHtR) against the other anthropometric 
measurements. In this study, Kahn and Bullard found that SADHtR was significantly 
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better at identifying cardiometabolic risks except for dysglycemia, in which WHtR better 
identified dysglycemia.12 
 
Cardiometabolic Risks 
Blood Pressure 
Based on data from NHANES 2009-2012, over 32 percent of US adult population 
has high blood pressure, or hypertension.37 According to the National Heart, Lung, and 
Blood Institute, high blood pressure is defined as a systolic blood pressure greater than or 
equal to 140 mm Hg or a diastolic blood pressure greater than or equal to 90 mm Hg. 
Self-reported use of anti-hypertensive medications was also used to define hypertension 
in this study. Left untreated, high blood pressure can lead to heart failure, heart attack, 
stroke, and many other complications. With such a high prevalence of blood pressure 
within the U.S., it is important to use measurements of obesity that can identify subjects 
at risk for hypertension. 
 
Anthropometric Measures and Blood Pressure Risk 
Many studies have been conducted observing blood pressure and various 
measures of general and abdominal obesity, but only several have been conducted on a 
nationally representative adult population, with only one on the U.S. population. A 
systematic review by Browning et al. found that WHtR and WC outperformed BMI in 
identifying risk of hypertension.9 A meta-analysis by Van Dijk et al. found that WC was 
moderately correlated with systolic blood pressure (SBP) and both WC and BMI with 
diastolic blood pressure among men and women. For both genders, WC was overall 
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significantly more correlated with CVD risk factors, including blood pressure, than BMI. 
WHtR was determined to be the least correlated with CVD risk factors. However, this 
sample also only consisted of Caucasians from different regions of the world.38 There is 
one meta-analysis by Savva et al. that observed a variety of ethnic groups. This analysis 
was slightly more comprehensive as its inclusion criteria was for elevated blood pressure, 
with a systolic blood pressure of 130 mm Hg or greater and/or a diastolic blood pressure 
of 85 mm Hg or greater. They also included participants that reported diagnosis from a 
physician or antihypertensive medication use. Based on pooled ratios of relative risk 
(rRR), neither BMI nor WHtR outperformed the other in regards to elevated blood 
pressure except among Asians, where WHtR was more favored. However, this finding 
lost strength once stratified by gender.39 
 
In terms of cross-sectional studies, there are two nationally representative study 
samples, one from Australia by Goh et al. and other from the U.S. by Kahn and Bullard. 
Goh et al. observed Australian women without a history of heart disease, diabetes or 
stroke. Their findings included that waist-to-hip ratio and waist-to-stature ratio (WHtR) 
were more correlated with CVD risk, including systolic blood pressure, than BMI and 
body adiposity index (BAI: hip circumference divided by height, subtracting 18 from the 
result).24 Kahn and Bullard conducted a cross-sectional study that was a nationally 
representative of the U.S. adult population. Comprising both genders and a variety of 
ethnicities, Kahn and Bullard were able to establish that odds ratios (ORs) adjusted for 
age, age-squared, and a quadratic term for each adiposity measure were highest for 
SADHtR and lowest for BMI in predicting risk of hypertension. When excluding 
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individuals taking antihypertensive drugs, the prevalence of hypertension dropped among 
men and women, but remained to be best identified by SADHtR. When competing with 
BMI, SADHtR was able to identify those with hypertension while BMI could not. 
However, when competing with BMI, neither WHtR nor BMI were able to identify 
individuals with hypertension. Of all of the studies mentioned, most found that measures 
of abdominal obesity including WC, WHtR, WHR, and SADHtR were better at assessing 
risk of high blood pressure than BMI. However, none of the abdominal obesity measures 
have been found to be consistently better than one another.12  
 
Pre-Diabetes 
According to the Centers for Disease Control and Prevention (CDC), over one 
third of the United States adult population has pre-diabetes, equating to about 86 million 
adults. Unfortunately, about 90 percent of these individuals are unaware they have pre-
diabetes.40 Along with increased risk of diabetes, pre-diabetes is known to increase risk 
of cardiovascular disease, stroke, and all-cause mortality.41 According to the American 
Diabetes Association, pre-diabetes is defined as a hemoglobin A1C between 5.7 – 6.4%, 
a fasting plasma glucose of 100-125 mg/dL, and/or a two hour blood glucose level of 
140-199 mg/dL following an oral glucose tolerance test. With such a high prevalence of 
pre-diabetes in the United States, screening methods are needed to identify those at risk 
for pre-diabetes. 
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Anthropometric Measures and Pre-Diabetes Risk 
Most studies that observe blood glucose or hemoglobin A1c levels focus strictly 
on diabetes risk rather than pre-diabetes risk. Only two studies comparing abdominal 
obesity measures analyzed individuals without a diagnosis of diabetes. One study by 
Kahn et al. from 2014 included individuals with diagnosed diabetes in their NHANES 
2011-2012 study sample and also included another group of individuals with a 
hemoglobin A1c equal to or greater than 5.7%, termed dysglycemia, but without a 
diabetes diagnosis. While this group may include those with undiagnosed diabetes, the 
efforts are primarily focused on identifying those with pre-diabetes. In this study, they 
found that when SAD and BMI quartiles were simultaneously analyzed in the same 
model, the prevalence of dysglycemia within the third and fourth quartiles for SAD was 
the greatest. Prevalence of dysglycemia was not significantly associated with the third 
and fourth quartiles for WC and BMI.8 
 
Another study by Kahn and Bullard in 2016 only included individuals without 
diagnosed diabetes in their NHANES 2011-2012 study sample and compared BMI, 
WHtR, and SADHtR with risk of dysglycemia, or a hemoglobin A1c of 5.7% or greater. 
In simultaneous competition with BMI, neither SADHtR nor BMI were able to identify 
individuals with dysglycemia. However, with WHtR in competition with BMI, WHtR 
was able to identify dysglycemia while BMI could not. With SADHtR and WHtR in 
simultaneous competition, neither was significantly different from one another in 
identifying dysglycemia.12 
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Diabetes 
In the United States, 1 in 10 adults have diabetes, with a majority of cases being 
type 2 diabetes.37 The American Diabetes Association defines diabetes as a hemoglobin 
A1C greater than or equal to 6.5%, a fasting blood glucose of 126 mg/dL or greater, 
and/or a two hour blood glucose level of 200 mg/dL or greater following an oral glucose 
tolerance test. With many complications including neuropathy, nephropathy, and 
retinopathy, diabetes can also increase risk of high blood pressure, cardiovascular 
disease, and stroke.42  
 
Anthropometric Measures and Diabetes Risk 
In regards to risk for diabetes, most studies have been conducted observing obese 
individuals rather than individuals of all weight statuses. A systematic review by 
Browning et al. identified that among prospective and cross-sectional studies, WHtR, 
WC, and BMI were equally significant predictors of diabetes in men and women.9 A 
meta-analysis by Van Dijk et al. showed that when comparing BMI, WC, WHtR, and 
WHR among men, WC had the strongest correlation with fasting blood glucose levels. 
WHtR was found to have the weakest correlation with fasting blood glucose. In women, 
WC and WHR were similarly correlated to fasting blood glucose, and WHtR was again 
the least correlated.39 In a meta-analysis by Savva et al. in 2013, diabetes was identified 
as a fasting blood glucose of 126 mg/dL or greater, a two hour post prandial blood 
glucose of 200 mg/dL or greater, a physician’s diagnosis of diabetes, and/or use of blood 
glucose lowering medications. In this study, the pooled rRR of WHtR and BMI were 
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found to be in favor of WHtR in the identification of persons with diabetes in Asians and 
non-Asians in cross-sectional studies, and just among Asians in prospective studies.39 
 
Very few cross-sectional studies exist focusing on the general population versus 
specific subgroups. A cross-sectional study by Pajunen et al. used Finland’s Health 2000 
Survey, focused on participants aged 30 years or older. This study did however consist of 
primarily Northern European Caucasians. Using multivariate models to account for 
lifestyle factors, it was found that BMI, WC, WHR, and SAD were all significant 
predictors of incident diabetes. Pairwise comparisons identified that the combination of a 
high BMI and high SAD was associated with the highest incidence of diabetes.43 This 
does not come as a surprise, as individuals with a high weight status and a higher 
concentration of visceral adipose tissue are already at a high risk for diabetes. 
 
Total Cholesterol 
Total cholesterol is a measure of serum LDL cholesterol, HDL cholesterol, and 
very low-density lipoprotein (VLDL) cholesterol. Based on NHANES 2009-2012 sample 
data, over 100 million US adults over the age of 20 have high total cholesterol (≥200 
mg/dL). Of these adults, nearly 31 million have total cholesterol levels of 240 mg/dL or 
greater.37 Total cholesterol is inexpensive to measure and does not require a fasted state, 
but cannot distinguish between the “good” and “bad” cholesterols. Total cholesterol is 
generally used in combination with other lipid measures to profile a complete lipid 
profile. High total cholesterol is defined as greater than or equal to 200 mg/dL or self-
reported use of lipid-lowering medications. 
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Anthropometric Measures and Total Cholesterol Risk 
While most studies involving the relationship of anthropometric measures 
evaluate total cholesterol, the primary outcomes are generally the incidence of CVD, or 
incidence of all cardiovascular events, rather than incidence of high total cholesterol. In a 
systematic review by Browning et al., WHtR, WC, and BMI did not differ in their ability 
to predict high total cholesterol.9 In a meta-analysis by Van Dijk et al., BMI, WC, and 
WHR among men were all similarly correlated with risk of high total cholesterol, with 
WHtR ratio only slightly less correlated. With women, WC and WHR were both found to 
be significantly better than BMI at predicting risk of high total cholesterol. Again, WHtR 
was the least correlated with high total cholesterol risk.38 Savva et al. found through 
meta-analysis that WHtR and BMI were not statistically significant in identifying 
dyslipidemia among all ethnic groups. WHtR was found statistically significant over BMI 
in identifying dyslipidemia among Asian populations, including men and women. It is 
important to note that dyslipidemia was used as a primary outcome, which does include 
hypercholesterolemia, but also several other abnormal lipid levels including LDL, HDL, 
and triglycerides.39 Given the variety of lipid measurements used in this outcome, it may 
explain for lack of significance in establishing a superior obesity measure. 
 
HDL Cholesterol 
According to CDC statistics from NHANES 2009-2010, about 31 percent of men 
and 12 percent of women had low HDL cholesterol in the United States.44 High-density 
lipoprotein cholesterol, or HDL cholesterol, is generally known as the “good” cholesterol. 
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HDL cholesterol aids in the removal of cholesterol from the body by delivering unused 
cholesterol to the liver for removal from the body.45 Higher levels of HDL cholesterol 
lower the risk of cardiovascular disease and stroke.21,46 Low HDL cholesterol has the 
opposite effect and is defined as less than 40 mg/dL. 
 
Anthropometric Measures and HDL Cholesterol Risk 
HDL cholesterol is a very commonly used measurement in current research, most 
likely related to its measurement not requiring a fasted state. However, it is generally not 
one of the primary outcomes, grouping it together with other cardiometabolic risk factors 
in metabolic syndrome or cardiovascular disease research. This has limited the number of 
research findings related to HDL cholesterol risk alone. In 2010, a systematic review by 
Browning et al. revealed that BMI, WC, and WHtR were all strongly correlated with risk 
of low HDL cholesterol.9 Van Dijk et al. found in a meta-analysis that WC and BMI were 
almost equally moderately correlated with low HDL risk among men and women, with 
higher correlations among women.38  
 
Non-HDL Cholesterol 
 Non-HDL cholesterol is calculated as the difference between serum total 
cholesterol and serum HDL cholesterol. This measurement is thought to be a better 
representation of “bad” cholesterol compared to serum total cholesterol, as it measures 
LDL cholesterol, and VLDL cholesterol, a transporter of cholesterol and triglycerides 
around the body. Based on NHANES 2005-2010 data, the prevalence of high non-HDL 
cholesterol among US adults is nearly 28 percent.47 According to the NCEP-III, patients 
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with triglycerides above 200 mg/dL should also have their serum non-HDL cholesterol 
levels monitored and kept within 30 mg/dL of their LDL cholesterol goal. Based on this 
guideline, high non-HDL cholesterol is defined as greater than or equal to 130 mg/dL. 
Non-HDL can also be measured in a non-fasted state, making it a quick measure to be 
used in screening risk for CVD. 
 
Anthropometric Measures and Non-HDL Cholesterol Risk 
A limited number of studies have been conducted comparing anthropometric 
measures and their ability to predict high non-HDL risk. A recent study with a similar 
design by Kahn et al. compared BMI, WHtR, and SADHtR in their ability to predict five 
cardiometabolic disorders, including “HyperNon-HDLc”, or high levels of non-HDL-C. 
Using data from NHANES 2011-2012, logistic regression models revealed that 
HyperNon-HDLc was best recognized by SADHtR. Among men and women, BMI was 
the weakest at predicting HyperNon-HDLc. When analyzed simultaneously, SADHtR 
and WHtR were comparable in identifying HyperNon-HDLc.12 These findings support 
the hypothesis that abdominal measures of obesity may be stronger predictors of risk than 
BMI alone, especially with identifying high non-HDL cholesterol. 
 
Apolipoprotein B 
ApoB is a key structural component of all lipoproteins, including LDL, VLDL, 
intermediate-density lipoprotein (IDL), chylomicrons, and lipoprotein (a) particles.48 
LDL cholesterol molecules tend to be heterogeneous in terms of cholesterol content. 
Individuals with a large number of LDL particles with little cholesterol content (or 
 18 
small/dense LDL particles) may have the same LDL concentration as an individual with 
fewer LDL particles that are high in cholesterol concentration (large, low density LDL 
particles). With one ApoB molecule per lipoprotein, ApoB measurements allow 
clinicians to distinguish LDL concentrations that may have a variable amount of 
cholesterol content.49 High Apo B is defined as a serum ApoB level of 80 mg/DL or 
greater, or self-reported use of lipid-lowering medications. Many studies have concluded 
that ApoB is a stronger screening tool for CVD than LDL, non-HDL concentrations, or 
other lipoprotein ratios 50–54, affirming its use as risk factor for research among normal 
weight and overweight individuals. 
 
Anthropometric Measures and ApoB risk 
To our knowledge, only one study has been conducted observing ApoB levels 
associated with measures of abdominal obesity. In this study by Onat et al.55, a single 
scan CT was performed on 157 Turkish participants, aged 34-69 years, in efforts to 
measure total adipose tissue area, abdominal visceral adipose tissue (VAT) area, and 
sagittal abdominal diameter in association with cardiovascular risk factors. Among the 
study population, 34% of participants had metabolic syndrome. Using linear regression 
analysis, ApoB and HDL-C were found to be independently associated with VAT area 
among men only. They also observed higher VAT areas in men compared to women for 
any given waist circumference as well as higher VAT areas in men compared to women 
for any given body fat mass. This suggests that men may be prone to a higher waist 
circumference thus a higher VAT area while at a lower BMI. With the measurement of 
ApoB as a cardiovascular risk factor being a fairly recent concern, more research needs to 
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be conducted to support its use as a predictive measure. ApoB has been measured by 
NHANES in both 2 year cycles used in this study and also does not require a fasted state 
to be measured, making it an ideal measure for use in this study. 
 
Normal Weight/Overweight Risk 
Given that obesity status generally has an exponential relationship with 
cardiometabolic disorders, it can be assumed that obese individuals are at much higher 
risk of developing cardiometabolic disorders than those that are normal weight or 
overweight. However, normal weight and overweight individuals may or may not be at as 
high of risk depending on the amount of visceral adipose tissue, which is more associated 
with disease risk compared to general obesity. In order to identify risk in these 
individuals, abdominal obesity measures may need to be compared in order to determine 
which can be most beneficial in identifying a variety of risk factors. To date, no studies 
have been performed observing a strictly normal weight or overweight population.  
 
National Health and Nutrition Examination Survey 
The National Health and Nutrition Examination Survey (NHANES) is an ongoing 
nationally representative, cross-sectional survey of the resident civilian, non-
institutionalized, United States population. The survey consists of a home interview 
including demographic, socioeconomic, dietary, and health-related questions. The 
examination at the mobile examination center (MEC) consists of medical, dental, and 
physiological measurements, and various laboratory tests. Visiting 15 counties around the 
country per year, NHANES collects data from about 5,000 people per year to develop a 
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two-year sample of about 10,000 participants. By oversampling older adults and certain 
ethnic groups, researchers can establish significant findings among these populations.56 
 
Until the 2011-2012 NHANES data cycle, SAD measurements had not previously 
been collected at the Mobile Examination Center (MEC). However, NHANES has 
continued to measure SAD since, allowing for two two-year data cycles to be available 
for research using this anthropometric measure. With only one-third of adult participants 
being in a fasted state for laboratory measurements, the use of cardiometabolic risk 
measurements that require a fasted state significantly lowers the study population. The 
use of laboratory measures that do not require a fasted state allow for the use of all 
subjects examined and tested at the MEC.  
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CHAPTER III 
 
JOURNAL ARTICLE  
 
RESEARCH SNAPSHOT 
Research Question: Are abdominal obesity measures more strongly associated with 
cardiometabolic risk than BMI, particularly in normal and overweight adults? And does 
height improve the ability of abdominal obesity measures to assess cardiometabolic risk? 
 
Key Findings: In this cross-sectional, nationally representative study that included 6482 
normal weight and overweight adults from the National Health and Nutrition 
Examination Survey of 2011-2014, body mass index could only identify risk of low high-
density lipoprotein cholesterol, while waist-to-height ratio, sagittal abdominal diameter, 
and sagittal abdominal diameter-to-height ratio identified six out of seven 
cardiometabolic risks.  
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ABSTRACT 
Background: It has been well established that screening tools for cardiometabolic 
diseases are less useful among obese populations as risk of these diseases is already high. 
However, research is lacking in regard to efficient screening tools for cardiometabolic 
diseases among normal weight and overweight populations.  
Objective: This study compared the predictive strengths of body mass index (BMI), 
waist circumference (WC), waist-to-height ratio (WHtR), sagittal abdominal diameter 
(SAD), and SAD-to-height ratio (SADHtR) with respect to risk of cardiometabolic 
disorders in normal and overweight U.S. populations.  
Design: This cross-sectional study utilized data from the 2011-2014 National Health and 
Nutrition Examination Survey.  
Participants/setting: The sample included non-pregnant adults with a normal weight or 
overweight BMI status (≥ 20 years; n = 6482).  
Main outcome measures: Each anthropometric measure was assessed for predicting risk 
of the following cardiometabolic disorders: hypertension (HTN), pre-diabetes, diabetes, 
high total cholesterol, low high-density lipoprotein cholesterol (HDL-C), high non-HDL-
C, and high apolipoprotein B.  
Statistical analyses performed: Simple and multiple logistic regression analyses 
compared the odds ratio of each anthropometric measure for each cardiometabolic 
disorder.  
Results: When analyzed in separate models, BMI, WC, WHtR, SAD, and SADHtR 
identified all cardiometabolic risks. In simultaneous models with abdominal obesity 
measures, BMI no longer identified cardiometabolic risks (ORs <1.0), except low HDL-
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C. Among normal weight and overweight men, WHtR and SADHtR were stronger 
measures of cardiometabolic risk except low HDL-C. With normal weight and 
overweight women, WHtR and SADHtR were stronger measures of risk for hypertension 
and diabetes, while all of the abdominal obesity measures were similar in assessment of 
the remaining cardiometabolic risks. 
Conclusion: In normal weight and overweight adults, anthropometric measures of 
abdominal obesity, especially those including a factor of height, are better predictors of 
cardiometabolic risk than BMI and should be a primary screening tool in this population.  
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INTRODUCTION/BACKGROUND 
While obesity rates in the United States (U.S.) have started to plateau based on 
body mass index (BMI) measurements, abdominal obesity rates are on the rise according 
to measures of waist circumference.1,2 Abdominal obesity, as compared with other 
distributions of adipose tissue, has specifically been shown to be highly associated with 
chronic diseases such as diabetes, cardiovascular diseases, and other cardiometabolic 
diseases.3–5 
BMI has traditionally been used for the assessment of body weight but has been 
shown to lack accuracy in terms of body composition. Waist circumference (WC), waist-
to-height ratio (WHtR), and sagittal abdominal diameter (SAD) are several measures that 
are used in assessing abdominal obesity, with SAD being a relatively newer measure. 
SAD is measured in the supine position using a caliper positioned in the center of the 
abdomen, midway between the left and right iliac crests, measuring the height of the 
abdomen, which has been shown to be associated with the amount of visceral fat in the 
abdomen. Since SAD measurements only require the use of a specialized caliper, this 
allows for the measurement to be easy, fast, and inexpensive compared to the more 
precise yet radiation-emitting magnetic resonance imaging and dual-energy x-ray 
absorptiometry.  
To date, a limited number of large-scale studies have been conducted evaluating 
SAD with various cardiometabolic risks in the U.S. adult population. A study in 2005 by 
Smith et al. found among men that SAD was a stronger predictor of coronary heart 
disease risk when divided by thigh circumference, known as the abdominal diameter 
index.6 In 2013, Gletsu-Miller et al. found that SAD was stronger at predicting levels of 
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visceral adipose tissue, and thus the ability to predict risk of dysglycemia, than WC after 
controlling for confounding variables among a small sample of severely obese women.7 
Similarly, in 2014, Kahn et al. found that SAD was associated with dysglycemia among 
men and women independently from WC and BMI in a nationally representative sample 
of the U.S. population.8 These findings suggest that SAD may be a useful screening tool 
in the U.S. population among men and women. 
Since WHtR has often been shown to be a better measure of abdominal obesity 
than WC alone, it is logical to expect that SAD may be more effectively used as the 
SAD-to-height ratio (SADHtR).9,10 Few studies have investigated the relationship 
between metabolic risks and SADHtR, with only two studies having been conducted in 
the U.S. population. One of the studies focused on various abdominal measures and their 
associations with sex, age, socioeconomic status, and ethnicity, rather than comparing 
efficacy of abdominal obesity measures.11 The second study compared several 
anthropometric measures, including SAD and SADHtR, against cardiometabolic risks in 
a nationally representative sample of the U.S. population using National Health and 
Nutrition Examination Survey (NHANES) 2011-2012 data. In that study, Kahn et al. 
found that SADHtR and WHtR were better at predicting risk of cardiometabolic disorders 
than BMI12; suggesting that SADHtR may be a better screening tool, especially compared 
to BMI. 
Current disease-related research focuses primarily on the whole population, 
including obese individuals. However, obese populations are already at a high risk of 
developing obesity-related diseases making abdominal obesity measures relatively 
unimportant. When determining a useful screening tool for obesity-related diseases, it is 
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important to find a tool that also works well in normal weight and overweight 
populations. In some studies, an overweight status has been suggested to be protective, 
especially among older adults.13,14 However, recent research suggests that an overweight 
BMI status based on highest lifetime BMI is associated with increased risk of 
cardiovascular and all-cause mortality.15 This implies the need for an abdominal obesity 
measure among normal weight and overweight populations that may predict disease risk 
before the development of the disease occurs. Therefore, the objectives of this study 
include: 1) to compare the predictive strengths of BMI, WC, WHtR, SAD, and SADHtR 
with respect to risk of cardiometabolic disorders in the normal and overweight U.S. adult 
population; 2) to compare WC against WHtR, and SAD against SADHtR ratio to 
determine whether height improves the predictive strengths; and 3) to compare WC 
against SAD and WHtR and SADHtR to determine which provides the strongest 
predictive strength of cardiometabolic disorders. It is hypothesized that abdominal 
obesity measures will be stronger than BMI in cardiometabolic risk prediction and that 
the inclusion of height with these measures will only strengthen their ability to assess 
risk. 
 
METHODS 
 
Study Population and Analytic Sample 
 The NHANES is an ongoing nationally representative, cross-sectional survey of 
the resident civilian, non-institutionalized, U.S. population. The survey consists of a 
home interview including demographic, socioeconomic, dietary, and health-related 
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questions. The examination at the mobile examination center (MEC) consists of medical, 
dental, and physiological measurements, as well as various laboratory tests.16 Several 
subgroups are oversampled, including Hispanics, non-Hispanic Asians, non-Hispanic 
blacks, and non-Hispanic whites over 80 years of age. Given this oversampling, sample 
weights are used to develop a distribution that is representative of the U.S. population.17 
Data from the NHANES 2011-2012 and 2012-2014 datasets were used to 
evaluate associations between various measurements of abdominal obesity and 
cardiometabolic risk factors.  Participants consisted of male and female adults of all 
ethnicities, aged 20+ years who participated in both the home interview and physical 
examination components of NHANES. Two samples were examined for this study, one 
consisting of the whole adult population (n = 10,723) stratified by gender and the other 
consisting of only adult participants with a normal weight or overweight BMI status (n = 
6482), also stratified by gender. Females who were pregnant or lactating were excluded 
from this study as well as participants with missing values for any of the anthropometric 
and/or laboratory tests. 
 
Anthropometric and Physiologic Measurements 
 Height, weight, WC, and SAD were measured according to NHANES protocols.18 
WHtR and SADHtR were calculated using the above measurements. Measurements of 
cardiometabolic risk included blood pressure, hemoglobin A1C, total cholesterol, high-
density lipoprotein-cholesterol (HDL-C), non-HDL-C, and Apoliprotein B (ApoB). 
These measures were chosen in part because they did not required a fasted blood sample 
and thus allowed for a greater sample size.  Descriptions of the examination and 
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laboratory methods used in this study are described in online NHANES documentation.19 
HTN was defined as having a blood pressure of 140/90 mm Hg or greater20, or self-
reported use of an anti-hypertensive medication. Pre-diabetes was defined as a having  a 
hemoglobin A1C of 5.7-6.4%, while diabetes was defined as a hemoglobin A1C of 6.5% 
or greater21, or self-reported use of insulin or a blood glucose lowering medication. High 
total cholesterol was defined as having a serum total cholesterol level of 200 mg/dL or 
greater, or self-reported use of a lipid lowering medication. Low HDL-C was defined as 
having a serum HDL-C level of less than 40 mg/dL.22 High non-HDL-C risk was defined 
as having a serum non-HDL-C level of 130 mg/dL or greater, or self-reported use of a 
lipid lowering medication. Lastly, high ApoB was defined as having a serum ApoB level 
of 80 mg/dL or greater, or self-reported use of a lipid lowering medication. 
 
Statistical Analysis 
 Weighted data was used in all statistical analyses using Statistical Analysis 
Software (SAS System version 9.2, SAS Institute Inc., Cary, North Carolina, USA). 
Simple logistic regression was performed to estimate the magnitude of the association 
between each anthropometric measurement with each cardiometabolic risk factor. 
Subjects were divided into quartiles based on each anthropometric measurement for 
determination of the odds ratios (ORs) for each cardiometabolic risk factor. The ORs of 
the first quartile, the reference group, was compared to the ORs of the fourth quartile to 
determine the strength of each measurement in the prediction of cardiometabolic risk. T-
tests were used to establish significant differences between the ORs for BMI and all other 
abdominal obesity measures for each cardiometabolic risk.  Because of the large number 
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of comparisons being made, a P-value of less than 0.01 was considered to be statistically 
significant. 
 To identify whether abdominal obesity measures were significantly different from 
one another in their predictive strength, we conducted multiple logistic regression 
analysis to simultaneously compare BMI with measures of abdominal obesity. Four 
models were used per cardiometabolic risk: BMI, WC, and WHtR; BMI, SAD, and 
SADHtR; BMI, WC, and SAD; and BMI, WHtR, and SADHtR. Significant differences 
were identified for measurements whose 95% confidence intervals (CI) did not overlap. 
For measurements that only had slight overlap of 95% CI, t-tests were performed to 
establish significant differences. 
 
RESULTS  
 The quartile cut-points for each anthropometric measurement for both the entire 
adult population and for just the normal weight and overweight population can be found 
in Table 1. The ORs of the fourth quartile compared to the first quartile of each 
cardiometabolic risk based on each anthropometric measurement for the adult male 
sample and the normal weight or overweight adult male sample are shown in Table 2. 
The ORs for all anthropometric measures were significantly greater in the fourth quartile 
than the first quartile for BMI and each measure of abdominal obesity for every 
cardiometabolic risk. While the data are not shown, it is also important to note that ORs 
consistently increased for with each quartile for each obesity measurement for all of the 
cardiometabolic risks. 
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Table 1. Means and quartile cut points based on gender for the NHANES 2011-2014 data 
sample. 
 
N/OW: normal and overweight, BMI: Body mass index, WC: Waist circumference, WHtR: Waist-to-height 
ratio, SAD: Sagittal abdominal diameter, SADHtR: SAD-to-height ratio. 
 
 Among all adult males, BMI was significantly weaker than most measures of 
abdominal obesity for predicting risk of HTN, diabetes, and high total cholesterol. There 
were no significant differences between BMI and measures of abdominal obesity for 
predicting risk of low HDL-C, high non HDL-C, and high ApoB.  Similarly, among 
normal and overweight adult males, most measures of abdominal obesity were 
statistically stronger than BMI at predicting risk of HTN, pre-diabetes, diabetes, and high 
total cholesterol. 
 
Table 2. Simple logistic regression analysis of cardiometabolic risks by each 
anthropometric measurement for all adult males and normal weight or overweight males 
of the NHANES 2011-2014 sample. 
 
Risk Measure 
All Adult Males NW/OW Males 
Odds Ratio 95% CI Odds Ratio 95% CI 
HTN 
BMI 3.69 2.84 - 4.79 2.31 1.73 - 3.07 
WC 6.93 5.17 - 9.30a 7.32 5.51 - 9.71a 
WHtR 8.42 6.27 - 11.31a 10.57 7.64 - 14.62a 
SAD 7.41 5.47 - 10.05a 7.04 4.66 - 10.64a 
SADHtR 8.06 6.03 - 10.77a 9.48 6.35 - 14.18a 
Pre-DM 
BMI 1.78 1.30 - 2.42 1.84 1.31 - 2.58 
WC 2.55 1.87 - 3.47 2.95 2.22 - 3.92 
WHtR 2.69 1.98 - 3.65 3.95 2.73 - 5.71a 
  Quartile Cut Points:  All Adults & N/OW Adults 
Males Females 
25p 50p 75p 25p 50p 75p 
All  
NW/
OW All 
NW/
OW All 
NW/
OW All 
NW/
OW All 
NW/
OW All 
NW/
OW 
BMI, kg/m2 24.2     23.3 27.4      25.5 31.3     27.6 23.8     22.4 28.2     24.8 33.7     27.3 
WC, cm 89.1     86.0 99.0      93.2 109.2  100.0 84.7     80.5 95.5     87.2 107.4     94.0 
WHtR 0.51     0.49 0.56      0.54 0.62     0.57 0.52     0.50 0.59     0.54 0.67     0.59 
SAD, cm 19.4     19.1   22.2     21.1 25.5     23.0 20.0     17.6 22.7     19.4 25.8     21.3 
SADHtR 0.114    0.110 0.130    0.121 0.147    0.133 0.117    0.110 0.135    0.121 0.157    0.133 
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SAD 3.01 2.29 - 3.96a 3.45 2.27 - 5.27 
SADHtR 3.06 2.30 - 4.09a 3.96 2.72 - 5.76a 
DM 
BMI 6.7 4.35 - 10.33 2.45 1.60 - 3.76 
WC 12.95 8.28 - 20.24 8.35 4.51 - 15.46a 
WHtR 19.09 9.97 - 36.57a 15.71 7.51 - 32.87a 
SAD 15.08 9.31 - 24.41a 11.58 5.30 - 25.32a 
SADHtR 23.48 11.63 - 47.43a 14.29 6.52 - 31.30a 
High TC 
BMI 2.43 1.89 - 3.12 2.38 1.80 - 3.16 
WC 3.68 2.72 - 4.96 5.60 3.96 - 7.93a 
WHtR 3.98 2.92 - 5.41a 6.36 4.41 - 9.16a 
SAD 4.02 3.06 - 5.28a 4.84 3.62 - 6.48a 
SADHtR 3.84 2.94 - 5.01a 6.00 4.39 - 8.19a 
Low HDL 
BMI 5.17 3.87 - 6.90 4.19 2.88 - 6.08 
WC 5.45 4.26 - 6.98 3.43 2.46 - 4.79 
WHtR 4.49 3.45 - 5.83 3.23 2.32 - 4.51 
SAD 6.28 4.92 - 8.02 4.67 3.16 - 6.89 
SADHtR 5.87 4.45 - 7.74 5.05 3.38 - 7.55 
High  
Non-HDL 
BMI 4.02 3.18 - 5.08 3.93 2.94 - 5.24 
WC 5.41 4.15 - 7.06 7.00 5.15 - 9.53 
WHtR 5.71 4.35 - 7.51 7.07 5.16 - 9.70 
SAD 5.82 4.56 - 7.41 6.51 4.96 - 8.56 
SADHtR 5.62 4.20 - 7.52 7.48 5.69 - 9.83a 
High ApoB 
BMI 4.06 2.84 - 5.81 2.96 1.95 - 4.48 
WC 5.18 3.29 - 8.16 4.60 2.97 - 7.15 
WHtR 5.31 3.47 - 8.12 6.23 3.85 - 10.09 
SAD 5.51 3.79 - 8.02 4.80 3.19 - 7.21 
SADHtR 5.09 3.19 - 8.10 6.97 4.78 - 10.17a 
 
NW/OW: normal and overweight, CI: confidence interval, HTN: hypertension, Pre-DM: Pre-diabetes, DM: 
Diabetes, TC: Total cholesterol, HDL: high-density lipoprotein, Non-HDL: non-high-density lipoprotein; 
ApoB: apolipoprotein B, BMI: body mass index, WC: waist circumference, WHtR: waist-to-height ratio, 
SAD: sagittal abdominal diameter, SADHtR: sagittal abdominal diameter-to-height ratio. 
Odds ratios represent Quartile 4 compared to Quartile 1.  
a Denotes significant difference from BMI (≤0.0001 P < 0.01) 
 
Table 3 reports the ORs of the fourth quartile compared to the first quartile of 
each cardiometabolic risk based on each anthropometric measurement for the adult 
female sample and the normal weight or overweight adult female sample by simple 
logistic regression. Among all adult females, BMI was significantly weaker than most 
abdominal obesity measures for predicting risk of HTN, diabetes, high non-HDL-C, and 
high total cholesterol. There were no differences between abdominal obesity measures 
and BMI with the risk assessment of low HDL-C and high ApoB. Among the normal 
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weight and overweight female sample, abdominal obesity measures were stronger than 
BMI when predicting risk for HTN, high, total cholesterol, high non-HDL-C, and high 
ApoB. There were no differences between abdominal obesity measures and BMI related 
to risk of pre-diabetes and low HDL-C. 
 
Table 3. Simple logistic regression analysis of cardiometabolic risks by each 
anthropometric measurement for all adult females and normal weight or overweight 
females of the NHANES 2011-2014 sample. 
 
Risk Measure 
All Adult Females NW/OW Females 
Odds Ratio 95% CI Odds Ratio 95% CI 
HTN 
BMI 3.32 2.63 - 4.18 1.92 1.30 - 2.86 
WC 5.07 3.89 - 6.60a 4.95 3.27 - 7.48a 
WHtR 7.03 5.02 - 9.86a 7.46 4.81 - 11.55a 
SAD 7.00 5.44 - 8.98a 8.90 6.01 - 13.19a 
SADHtR 8.00 6.22 - 10.29a 11.19 7.15 - 17.52a 
Pre-DM 
BMI 2.72 2.10 - 3.52 2.47 1.63 - 3.74 
WC 2.8 2.08 - 3.77 5.05 3.46 - 7.36 
WHtR 3.73 2.75 - 5.05 5.16 3.17 - 8.40 
SAD 3.04 2.08 - 4.43 4.20 2.62 - 6.75 
SADHtR 3.55 2.49 - 5.06 4.80 3.02 - 7.64 
DM 
BMI 9.44 6.62 - 13.46 3.90 2.62 - 5.81 
WC 14.93 10.27 - 21.71b 14.77 8.45 - 25.83 
WHtR 32.23 20.58 - 50.48a b 36.01 13.59 - 95.47 
SAD 21.24 12.66 - 35.64a 15.98 8.27 - 30.86 
SADHtR 26.49 15.99 - 43.89a 30.61 11.09 - 84.49 
High TC 
BMI 1.75 1.42 - 2.16 2.04 1.52 - 2.73 
WC 2.36 1.87 - 2.96 3.40 2.62 - 4.42 
WHtR 2.73 2.15 - 3.45a 3.93 3.00 - 5.14a 
SAD 2.46 1.99 - 3.03 4.46 3.46 - 5.75a 
SADHtR 2.53 2.06 - 3.11a 4.69 3.56 - 6.17a 
Low HDL 
BMI 7.73 4.72 - 12.67 6.13 3.70 - 10.14 
WC 11.91 7.29 - 19.45 8.32 3.04 - 22.74 
WHtR 12.21 6.62 - 22.53 11.73 4.09 - 33.66 
SAD 10.30 5.49 - 19.33 10.35 5.75 - 18.63 
SADHtR 9.3 5.11 - 16.92 9.00 3.79 - 21.40 
High  
Non-HDL 
BMI 3.22 2.68 - 3.87 3.12 2.29 - 4.27 
WC 4.26 3.38 - 5.38 4.90 3.62 - 6.62 
WHtR 4.99 3.96 - 6.29a 6.06 4.38 - 8.37a 
SAD 4.66 3.82 - 5.69a 6.13 4.66 - 8.05a 
SADHtR 4.75 3.98 - 5.66a 6.97 5.17 - 9.40a 
High ApoB 
BMI 3.25 2.41 - 4.37 2.80 1.97 - 3.99 
WC 4.16 3.08 - 5.62 4.67 3.17 - 6.87 
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WHtR 4.39 3.34 - 5.77 8.47 5.43 - 13.22 
SAD 4.88 3.44 - 6.92 6.85 4.85 - 9.66 
SADHtR 4.87 3.69 - 6.43 7.24 5.10 - 10.27 
 
NW/OW: normal and overweight, CI: confidence interval, HTN: hypertension, Pre-DM: Pre-diabetes, DM: 
Diabetes, TC: Total cholesterol, HDL: high-density lipoprotein, Non-HDL: non-high-density lipoprotein; 
ApoB: apolipoprotein B, BMI: body mass index, WC: waist circumference, WHtR: waist-to-height ratio, 
SAD: sagittal abdominal diameter, SADHtR: sagittal abdominal diameter-to-height ratio. 
Odds ratios represent Quartile 4 compared to Quartile 1.  
a Denotes significant difference from BMI (≤0.0001 P < 0.01) 
b Denotes significant difference between WC and WHtR (P <0.01) 
 
Table 4 shows results of multiple logistic regression analysis for all adult males, 
and separately for normal weight and overweight males, with the OR of quartile four 
compared to quartile one. When used in simultaneous models with abdominal obesity 
measures, BMI was no longer able to identify any of the cardiometabolic risks (ORs < 
1.0), except low HDL-C (ORs = 1.80 - 3.14), among all male adults, and normal weight 
and overweight male adults. With all adult males, WHtR outperformed WC in the 
prediction of risk for four out of seven cardiometabolic risks, while WHtR and WC were 
equally stronger predictors than BMI for two out of seven cardiometabolic risks. 
SADHtR only outperformed SAD in predicting risk of diabetes, while SAD and SADHtR 
were equal predictors of risk for four out of seven cardiometabolic risks. SAD was a 
stronger predictor than WC in risk for two out of seven cardiometabolic risks, while SAD 
and WC were similar predictors of risk for five out of seven cardiometabolic risks. WHtR 
and SADHtR were similar predictors of all cardiometabolic risks except for low HDL-C. 
In terms of risk of low HDL-C, BMI and WC were equally stronger predictors than 
WHtR. BMI and SAD were also equally stronger predictors of low-HDL-C than WC. 
BMI and SADHtR were similar predictors for risk of low-HDL-C compared to WHtR. 
With normal weight and overweight adult males, WHtR was stronger than WC in 
the prediction of risk for five out of seven cardiometabolic risks, while WC and WHtR 
 40 
were similar predictors of risk for high non-HDL-C. SADHtR was a better predictor than 
SAD for risk of all cardiometabolic risks except for low HDL-C.  SAD was a stronger 
predictor than WC in the assessment of risk for diabetes, while SAD and WC were 
similar predictors for all remaining cardiometabolic risks except low HDL-C. SADHtR 
was stronger than WHtR in the prediction of risk for high ApoB, while SADHtR and 
WHtR were similar predictors of risk for all other cardiometabolic risks except low HDL-
C.  For risk of low HDL-C, BMI and SAD outperformed WC, and BMI and SADHtR 
outperformed WHtR in the assessment of low HDL-C risk.  
 
Table 4. Multiple logistic regression analysis of cardiometabolic risks by each 
anthropometric measurement for all adult males and normal weight or overweight males 
of the NHANES 2011-2014 sample. 
 
Risk Measure 
All Adult Males NW/OW Males 
Odds Ratio 95% CI Odds Ratio 95% CI 
HTN 
BMI 0.20 0.12 - 0.33 0.24 0.14 - 0.41 
WC 3.20 1.51 - 6.77a 2.00 1.01 - 3.96ab 
WHtR 12.19 6.19 - 23.99a 17.42 9.29 - 32.67ab 
BMI 0.31 0.17 - 0.56 0.35 0.21 - 0.59 
SAD 3.81 1.82 - 7.96a 1.56 0.79 - 3.09ac 
SADHtR 6.59 3.43 - 12.66a 13.57 6.81 - 27.06ac 
BMI 0.27 0.14 - 0.50 0.35 0.20 - 0.62 
WC 4.29 2.15 - 8.54a 4.48 2.30 - 8.74a 
SAD 6.41 3.21 - 12.80a 4.66 2.33 - 9.32a 
BMI 0.22 0.13 - 0.37 0.21 0.13 - 0.36 
WHtR 7.62 4.53 - 12.82a 8.25 4.34 - 15.68a 
SADHtR 4.89 2.90 - 8.24a 5.39 2.68 - 10.84a 
Pre-
DM 
BMI 0.30 0.19 - 0.48 0.47 0.30 - 0.75 
WC 1.35 0.74 - 2.46ab 1.04 0.52 - 2.07b 
WHtR 5.76 3.08 - 10.79ab 6.39 2.95 - 13.85ab 
BMI 0.30 0.19 - 0.47 0.58 0.40 - 0.85 
SAD 2.09 1.02 - 4.28a 1.16 0.51 - 2.65 
SADHtR 4.25 2.16 - 8.37a 5.26 2.58 - 10.73a 
BMI 0.36 0.22 - 0.57 0.61 0.37 - 0.99 
WC 1.40 0.75 - 2.62ad 1.93 1.09 - 3.43a 
SAD 5.12 2.70 - 9.70ad 2.71 1.38 - 5.34a 
BMI 0.24 0.15 - 0.39 0.42 0.28 - 0.64 
WHtR 2.34 1.18 - 4.64a 3.39 1.73 - 6.68a 
SADHtR 4.27 2.22 - 8.22a 2.55 1.43 - 4.55a 
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DM 
BMI 0.26 0.14 - 0.46 0.23 0.13 - 0.41 
WC 2.14 0.85 - 5.36ab 1.13 0.52 - 2.46ab 
WHtR 31.88 10.35 - 98.17ab 44.85 20.08 - 100.16ab 
BMI 0.32 0.17 - 0.59 0.26 0.15 - 0.47 
SAD 2.03 0.74 - 5.61ac 1.97 0.54 - 7.11ac 
SADHtR 31.43 9.18 - 107.55ac 22.44 6.78 - 74.23ac 
BMI 0.37 0.21 - 0.67 0.36 0.20 - 0.65 
WC 3.01 1.31 - 6.93a 2.30 0.96 - 5.50ad 
SAD 13.32 5.61 - 31.59a 13.26 4.96 - 35.43ad 
BMI 0.21 0.12 - 0.37 0.18 0.10 - 0.32 
WHtR 6.43 3.15 - 13.11a 8.54 2.74 - 26.66a 
SADHtR 16.12 7.44 - 34.92a 9.60 3.19 - 28.90a 
High 
TC 
BMI 0.27 0.19 - 0.39 0.35 0.22 - 0.55 
WC 2.32 1.35 - 4.00a 2.84 1.79 - 4.50ab 
WHtR 5.77 3.13 - 10.64a 5.55 3.02 - 10.20ab 
BMI 0.36 0.24 - 0.54 0.5 0.33 - 0.76 
SAD 3.58 1.99 - 6.45a 1.47 0.99 - 2.19ac 
SADHtR 2.96 1.66 - 5.29a 6.747 4.08 - 11.16ac 
BMI 0.32 0.23 - 0.45 0.42 0.29 - 0.62 
WC 2.47 1.39 - 4.39a 4.67 2.66 - 8.21a 
SAD 4.89 2.65 - 9.04a 2.55 1.66 - 3.92a 
BMI 0.28 0.19 - 0.42 0.35 0.21 - 0.59 
WHtR 4.78 2.70 - 8.47a 4.32 2.34 - 7.97a 
SADHtR 2.79 1.65 - 4.71a 3.79 2.37 - 6.04a 
Low 
HDL 
BMI 3.14 2.21 - 4.45 2.87 1.65 - 5.01 
WC 2.43 1.32 - 4.46 1.42 0.70 - 2.91 
WHtR 0.8 0.40 - 1.58a 1.14 0.59 - 2.18 
BMI 1.89 1.31 -2.74 1.80 1.12 - 2.89 
SAD 1.76 1.03 - 3.00 1.87 0.89 - 3.94 
SADHtR 2.16 1.15 - 4.05 1.93 0.88 - 4.22 
BMI 2.35 1.63 - 3.40 2.44 1.38 - 4.31 
WC 0.85 0.54 - 1.33ad 0.52 0.25 - 1.07d 
SAD 3.61 2.24 - 5.82d 4.55 2.48 - 8.33d 
BMI 3.03 2.06 - 4.45 2.51 1.53 - 4.13 
WHtR 0.36 0.18 - 0.71ae 0.43 0.24 - 0.80e 
SADHtR 6.13 3.13 - 11.98e 5.44 2.92 - 10.17e 
High 
Non-
HDL 
BMI 0.54 0.33 - 0.91 0.73 0.45 - 1.20 
WC 2.13 1.14 - 3.99a 2.69 1.58 - 4.57a 
WHtR 5.01 2.31 - 10.85a 3.71 1.84 - 7.44a 
BMI 0.60 0.38 - 0.94 0.91 0.57 - 1.44 
SAD 2.93 1.55 - 5.55a 1.55 0.85 - 2.83 
SADHtR 3.50 1.71 - 7.14a 5.35 2.62 - 10.93a 
BMI 0.57 0.38 - 0.87 0.79 0.53 - 1.19 
WC 2.09 1.18 - 3.73a 3.28 1.96 - 5.52a 
SAD 5.08 2.86 - 9.04a 2.85 1.88 - 4.33a 
BMI 0.51 0.29 - 0.88 0.73 0.41 - 1.29 
WHtR 3.29 1.72 - 6.27a 2.46 1.41 - 4.31a 
SADHtR 3.56 2.08 - 6.08a 4.33 2.89 - 6.48a 
High BMI 0.58 0.26 - 1.29 0.58 0.27 - 1.24 
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ApoB WC 1.37 0.48 - 3.91 2.36 1.18 - 4.71 
WHtR 6.81 2.74 - 16.91a 4.33 1.96 - 9.59a 
BMI 0.66 0.33 - 1.30 0.70 0.39 - 1.26 
SAD 2.17 0.87 - 5.41 1.38 0.66 - 2.90c 
SADHtR 3.82 1.26 - 11.58 6.89 3.50 - 13.56ac 
BMI 0.72 0.36 - 1.45 0.57 0.29 - 1.12 
WC 1.6 0.53 - 4.89 2.92 1.27 - 6.73a 
SAD 4.96 1.99 - 12.39a 3.01 1.53 - 5.89a 
BMI 0.5 0.24 - 1.03 0.55 0.26 - 1.14 
WHtR 3.57 1.35 - 9.43a 2.51 0.99 - 6.34 
SADHtR 2.93 1.04 - 8.24a 5.60 3.04 - 10.30a 
 
NW/OW: normal and overweight, CI: confidence interval, HTN: hypertension, Pre-DM: Pre-diabetes, DM: 
Diabetes, TC: Total cholesterol, HDL: high-density lipoprotein, Non-HDL: non-high-density lipoprotein; 
ApoB: apolipoprotein B, BMI: body mass index, WC: waist circumference, WHtR: waist-to-height ratio, 
SAD: sagittal abdominal diameter, SADHtR: sagittal abdominal diameter-to-height ratio. 
Odds ratios represent Quartile 4 compared to Quartile 1.  
a Denotes significant difference from BMI (≤0.0001 P < 0.01), b Denotes significant difference between 
WC and WHtR,  c Denotes significant difference between SAD and SADHtR,   d Denotes significant 
difference between WC and SAD,  e Denotes significant difference between WHtR and SADHtR. 
 
The results of multiple logistic regression analysis for all adult females, and 
normal weight and overweight females are reported in Table 5. The OR of quartile four 
was compared to the OR of quartile one. In simultaneous models with abdominal obesity 
measures, BMI was not able to identify any of the cardiometabolic risks (ORs < 1.0), 
except low HDL-C (ORs = 0.77-1.92), among all adult females as well as normal weight 
and overweight females. Among all adult females, WHtR is a stronger predictor than WC 
for four out of seven cardiometabolic risks, while WHtR and WC are similar predictors 
for two out of seven cardiometabolic risks. SADHtR is stronger than SAD in the 
prediction of all cardiometabolic risks except low HDL-C. SAD is a stronger predictor 
than WC for risk of HTN and pre-diabetes, while SAD and WC are similar predictors for 
risk of four out of seven cardiometabolic risks. SADHtR is stronger than WHtR in the 
risk assessment of HTN, while SADHtR and WHtR are similar predictors of risk for all 
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other cardiometabolic risks except low HDL-C. For risk of low HDL-C, WHtR was 
stronger than BMI and WHtR was stronger than BMI when in a model with SADHtR. 
 With normal weight and overweight adult females, WHtR was a stronger 
predictor than WC for five out seven cardiometabolic risks, while WHtR and WC were 
similar predictors of risk for pre-diabetes. SADHtR was a stronger predictor of risk than 
SAD for HTN and diabetes, while SADHtR and SAD were similar predictors of four out 
of seven cardiometabolic risks. SAD was a better predictor than WC for two out of seven 
cardiometabolic risks, while SAD and WC were similar predictors of risk for all 
remaining cardiometabolic risks except low HDL-C. SADHtR and WHtR were similar 
predictors of risk for all cardiometabolic risks except low HDL-C. With risk of low HDL-
C, there were no significant differences between all measures for each comparison model. 
 
Table 5. Multiple logistic regression analysis of cardiometabolic risks by each 
anthropometric measurement for all adult females and normal weight or overweight 
females of the NHANES 2011-2014 sample. 
 
Risk Measure 
All Adult Females NW/OW Females 
Odds Ratio 95% CI Odds Ratio 95% CI 
HTN 
BMI 0.19 0.13 - 0.29 0.18 0.09 - 0.35 
WC 1.93 1.01 - 3.68ab 1.41 0.65 - 3.09ab 
WHtR 17.17 9.23 - 31.93ab 21.64 10.23 - 45.80ab 
BMI 0.13 0.08 - 0.20 0.16 0.08 - 0.33 
SAD 3.68 2.04 - 6.64ac 2.79 1.08 - 7.22ac 
SADHtR 13.97 7.54 - 25.89ac 17.92 7.56 - 42.45ac 
BMI 0.15 0.10 - 0.23 0.19 0.10 - 0.37 
WC 2.13 1.21 - 3.75ad 2.11 1.27 - 3.51ad 
SAD 18.83 11.50 - 30.84ad 16.5 8.76 - 31.07ad 
BMI 0.11 0.07 - 0.17 0.12 0.06 - 0.22 
WHtR 4.45 2.71 - 7.30ae 4.80 2.22 - 10.38a 
SADHtR 15.93 10.09 - 25.15ae 14.77 7.48 - 29.15a 
Pre-DM 
BMI 0.74 0.46 - 1.20 0.47 0.27 - 0.80 
WC 0.89 0.54 - 1.48b 2.81 1.69 - 4.66a 
WHtR 5.29 2.98 - 9.38ab 4.7 1.97 - 11.23a 
BMI 0.61 0.38 - 0.98 0.63 0.39 - 1.02 
SAD 0.90 0.39 - 2.05c 2.37 1.08 - 5.21a 
SADHtR 5.98 2.84 - 12.58ac 3.24 1.49 - 7.04a 
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BMI 0.8 0.47 - 1.34 0.52 0.32 - 0.85 
WC 1.1 0.67 - 1.83d 3.08 1.97 - 4.81a 
SAD 3.41 1.86 - 6.26ad 3.47 2.03 - 5.93a 
BMI 0.49 0.29 - 0.81 0.51 0.29 - 0.88 
WHtR 1.78 0.92 - 3.46e 3.67 1.71 - 7.88a 
SADHtR 4.26 2.23 - 8.15e 3.15 1.89 - 5.25a 
DM 
BMI 0.29 0.15 - 0.55 0.2 0.11 - 0.36 
WC 1.14 0.45 - 2.87b 1.27 0.51 - 3.15ab 
WHtR 88.24 32.92 - 236.52ab 107.46 26.58 - 434.49ab 
BMI 0.43 0.23 - 0.83 0.39 0.17 - 0.90 
SAD 1.96 0.69 - 5.57c 0.91 0.23 - 3.58c 
SADHtR 29.93 11.19 - 80.03ac 68.24 12.05 - 386.60ac 
BMI 0.4 0.21 - 0.79 0.34 0.18 - 0.65 
WC 3.91 1.37 - 11.19a 8.69 3.29 - 22.96a 
SAD 14.12 4.28 - 46.56a 7.01 2.33 - 21.14a 
BMI 0.18 0.10 - 0.32 0.17 0.10 - 0.31 
WHtR 22.66 7.98 - 64.34a 32.71 5.90 - 181.22a 
SADHtR 9.06 3.15 - 26. 04a 7.76 1.53 - 39.40a 
High TC 
BMI 0.27 0.16 - 0.46 0.43 0.27 - 0.67 
WC 1.78 1.15 - 2.75ab 1.54 0.93 - 2.55ab 
WHtR 5.06 3.11 - 8.24ab 4.99 2.77 - 8.96ab 
BMI 0.28 0.18 - 0.45 0.45 0.28 - 0.74 
SAD 1.55 0.89 - 2.68ac 2.34 1.44 - 3.79a 
SADHtR 5.31 2.96 - 9.54ac 3.80 2.10 - 6.90a 
BMI 0.27 0.17 - 0.44 0.43 0.27 - 0.68 
WC 2.35 1.46 - 3.78a 1.8 1.07 - 3.04a 
SAD 3.74 2.56 - 5.46a 4.73 2.82 - 7.94a 
BMI 0.21 0.12 - 0.37 0.36 0.22 - 0.59 
WHtR 2.78 1.72 - 4.49a 2.69 1.46 - 4.95a 
SADHtR 4.39 3.10 - 6.22a 3.98 2.20 - 7.22a 
Low HDL 
BMI 0.77 0.40 - 1.48 1.30 0.63 - 2.68 
WC 3.32 1.26 - 8.76 1.46 0.44 - 4.86 
WHtR 5.55 1.75 - 17.59a 7.29 2.09 - 25.20 
BMI 1.28 0.61 - 2.71 1.92 0.95 - 3.90 
SAD 4.44 1.11 - 17.74 3.02 0.70 - 13.06 
SADHtR 2.06 0.70 - 6.05 2.72 0.60 - 12.28 
BMI 0.81 0.39 - 1.70 1.53 0.74 - 3.18 
WC 5.03 2.12 - 11.94a 2.40 0.92 - 5.90 
SAD 3.76 1.25 - 11.30 3.92 1.30 - 11.82 
BMI 0.86 0.43 - 1.74 1.28 0.66 - 2.50 
WHtR 8.47 3.42 - 20.98a 6.68 1.62 - 27.58 
SADHtR 2.05 1.01 - 4.19 1.9 0.57 - 6.33 
High 
Non-HDL 
BMI 0.44 0.28 - 0.70 0.61 0.40 - 0.92 
WC 1.79 1.10 - 2.93ab 1.33 0.82 - 2.17b 
WHtR 6.09 3.56 - 10.41ab 6.63 3.76 - 11.69ab 
BMI 0.46 0.30 - 0.70 0.64 0.38 - 1.07 
SAD 1.65 0.88 - 3.11ac 1.69 1.07 - 2.65ac 
SADHtR 6.40 3.63 - 11.29ac 5.88 3.51 - 9.85ac 
BMI 0.45 0.30 - 0.67 0.65 0.42 - 1.00 
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WC 2.43 1.42 - 4.18a 1.86 1.06 - 3.25a 
SAD 4.60 2.77 - 7.62a 4.64 2.73 - 7.88a 
BMI 0.32 0.20 - 0.53 0.47 0.29 - 0.77 
WHtR 3.04 1.87 - 4.92a 2.86 1.45 - 5.65a 
SADHtR 5.34 3.80 - 7.50a 4.68 2.48 - 8.85a 
High 
ApoB 
BMI 0.45 0.22 - 0.94 0.54 0.28 - 1.03 
WC 2.00 0.89 - 4.49 0.90 0.37 - 2.17b 
WHtR 4.67 1.83 - 11.89a 13.41 6.88 - 26.15ab 
BMI 0.4 0.19 - 0.82 0.49 0.25 - 0.95 
SAD 1.82 0.48 - 6.84 2.10 0.97 - 4.56a 
SADHtR 6.57 2.12 - 20.37a 5.97 3.01 - 11.83a 
BMI 0.4 0.19 - 0.81 0.58 0.28 - 1.19 
WC 2.01 1.07 - 3.76ad 1.20 0.56 - 2.57d 
SAD 6.11 2.67 - 13.97ad 7.98 3.93 - 16.23ad 
BMI 0.32 0.14 - 0.74 0.37 0.19 - 0.70 
WHtR 2.14 0.99 - 4.60a 4.32 1.76 - 10.60a 
SADHtR 6.87 3.58 - 13.21a 4.65 1.99 - 10.87a 
 
NW/OW: normal and overweight, CI: confidence interval, HTN: hypertension, Pre-DM: Pre-diabetes, DM: 
Diabetes, TC: Total cholesterol, HDL: high-density lipoprotein, Non-HDL: non-high-density lipoprotein; 
ApoB: apolipoprotein B, BMI: body mass index, WC: waist circumference, WHtR: waist-to-height ratio, 
SAD: sagittal abdominal diameter, SADHtR: sagittal abdominal diameter-to-height ratio. 
Odds ratios represent Quartile 4 compared to Quartile 1.  
a Denotes significant difference from BMI (≤0.0001 P < 0.01), b Denotes significant difference between 
WC and WHtR,  c Denotes significant difference between SAD and SADHtR,   d Denotes significant 
difference between WC and SAD,  e Denotes significant difference between WHtR and SADHtR. 
 
DISCUSSION 
In the current study, it is apparent that abdominal measures that include height are 
able to better predict many cardiometabolic risks among both males and females. Among 
normal weight and overweight males, WHtR and SADHtR were the strongest predictors 
of all cardiometabolic risks except low HDL-C. With normal weight and overweight 
females, WHtR and SADHtR appear to be the best measures of risk for HTN and 
diabetes, while the remaining cardiometabolic risks are predicted quite similarly between 
abdominal obesity measures, except for low HDL-C. While WHtR and SADHtR may not 
be significantly different from each other in disease risk assessment, both are consistently 
better than abdominal obesity measures that do not include a factor of height and 
especially superior to BMI. Factoring height into various abdominal measurements may 
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help better predict risk of cardiometabolic diseases. Height can help to distinguish 
between individuals with larger midsections related to their small or large stature versus 
individuals with a high level of visceral adiposity. Many studies have supported this 
theory, justifying that WHtR is a better measure than waist circumference alone.9,23–26 
Overall, very few studies have been published using the general population versus 
specific populations, such as severely obese individuals, gender, ethnicity, or age specific 
studies. This proves difficult in comparing the current findings to such studies. However, 
one study12 by Kahn and Bullard found SADHtR and WHtR tended to have higher ORs 
than BMI for several cardiometabolic risks, but when compared against each other, found 
that SADHtR identified better with HTN, hyper-alanine transaminase and hyper-
gammaglutamyltransferase than did WHtR. While there are similarities to the study by 
Kahn and Bullard, the current study included measures of diabetes, high total cholesterol, 
low HDL-C and high ApoB as cardiometabolic risk factors. ORs for WHtR and SADHtR 
were the highest among males and females for most cardiometabolic risks congruent with 
findings by Kahn et al., except that study found SADHtR to be the strongest measure in 
most cases. Kahn’s study also did not include WC or SAD in their comparisons, leaving 
out an important aspect of this research as SAD tended to have higher ORs for several 
cardiometabolic risks compared to the other abdominal obesity measures. Also, the 
inclusion of WC and SAD allowed for the comparisons that included height helping to 
identify whether the inclusion of height contributed to stronger risk assessment.  
Gletsu-Miller et al. published a study7 involving 60 clinically severely obese 
women in efforts to predict visceral adiposity in association with dysglycemia. When 
comparing to BMI and WC, they found SAD to be a better estimate of visceral adiposity 
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and most associated with dysglycemia related to decreased beta-cell function. The current 
study demonstrated similar findings, as SAD was a stronger predictor of pre-diabetes 
than WC among all adult females. With these results showing the fourth quartile 
compared to the first quartile, this also coincides with that study, as the fourth quartile 
among all adult females likely consists of mostly obese females. However, in the current 
study, WHtR and SADHtR, while not significantly different from one another, were 
stronger predictors than WC and SAD. While notable, this finding expands on Gletsu-
Miller et al.’s findings, as measures of height were not used in that study.  
Smith et al. published a study6 observing a cohort of 466 male participants in 
regards to various anthropometric measures of obesity and their relation to known 
coronary heart disease risk factors. When comparing BMI, WC, WHR, waist-thigh ratio, 
SAD, and abdominal diameter index, Smith et al. found that abdominal diameter index 
was the strongest at predicting risk of coronary heart disease after adjusting for 10-year 
Framingham CHD risk. Abdominal diameter index is a ratio of SAD and thigh 
circumference, emphasizing the increased importance of the use of SAD. One important 
difference in that study was the absence of height in the anthropometric measurements. 
Overall, the ORs for each of the anthropometric measures were very comparable and 
quite possibly not significantly different than one another, as tests of significance 
between each anthropometric measure were not conducted. With the absence of height, 
obesity measures tended to be very similar predictors of coronary heart disease among 
men, accentuating the need for an enhanced measure of obesity for disease risk 
prediction. With the current study’s findings, it is clear that including measures of height 
increase the ability to predict cardiometabolic risk, including heart disease risk factors. 
 48 
While the current study has many strengths, including a large nationally 
representative sample consisting of four years of data, the use of ratios of abdominal 
obesity to height in predicting metabolic risks, gender stratification, and a focus on the 
normal weight and overweight adult population, it also has some limitations. One 
limitation of this study was the use of only non-fasted laboratory measurements. While 
there are many fasted laboratory measures that could assist with defining each 
cardiometabolic risk and also allow for the use other cardiometabolic risks, only a third 
of the participants at the MEC could be utilized, as only the morning group of 
participants was required to be fasted. This significantly lowered the sample size, making 
it more difficult to stratify based on normal weight or overweight status and gender. As 
NHANES continues to measure SAD, future studies may be able to use more sample 
years that could allow for the use of fasted laboratory measures. However, the laboratory 
measures used in this research are adequate in defining cardiometabolic diseases.  
Additionally, several measures of abdominal obesity were not included in this 
research. Abdominal index, which is defined as waist circumference to thigh 
circumference to height ratio, was not included among the anthropometric measures as 
thigh circumference is not included in the NHANES physiological measurements. Hip 
circumference is also not included among NHANES measurements, eliminating the 
possible use of waist-hip-height ratio, a fairly new measurement. Several studies6,27,28 
have included abdominal index and waist-hip-height ratio, making them intriguing 
measures for future research. 
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CONCLUSIONS 
Abdominal measures of obesity were better predictors of risk for all 
cardiometabolic disorders except low HDL-C in the normal weight and overweight 
populations. Factoring height into the abdominal obesity measurements improved the 
assessment of cardiometabolic disease risk. WHtR and SADHtR tended to be the best 
measures for risk assessment among men and women. While some of the abdominal 
measures of obesity were not significantly different than one another for some 
cardiometabolic risks, all were better predictors of disease risk than BMI. Abdominal 
measures of obesity, particularly those that include height, should be considered for use 
in clinical practice to strengthen the ability to predict risk of cardiometabolic diseases 
among normal weight and overweight populations.  
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